The Belfer Institute Mission
The mission of the Belfer Institute for Applied Cancer Science is to integrate academic, industry and clinical resources/expertise to enhance success in oncology drug discovery.
There are nearly 12 million people in the U.S. living with cancer and half of all men and one-third of all women in the U.S. will develop cancer in their lifetimes. While cancer therapies are improving and some cancers can now be treated effectively, there still remains a critical unmet medical need for safe and effective treatments. We believe that the next generation of cancer therapies will be identified out of emerging cancer genomics research and our goal is to help develop revolutionary new therapies that target specific molecular aberrations and attack cancer’s root causes.
In the News
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.
Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.
Findings from the Translational Research Lab within the Belfer Institute demonstrate that circulating DNA from non-invasive plasma samples is a promising biomarker to monitor response and predict resistance in the clinic.
Belfer scientists collaborate with W. Kaelin MD , to demonstrate that the Ikaros family of transcription factors are key downstream mediators of the efficacy of thalidomide-like drugs.